NASDAQ:HJLI - Hancock Jaffe Laboratories Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.28
▼ -0.09 (-1.22%)
1 month | 3 months | 12 months
Get New Hancock Jaffe Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HJLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HJLI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Hancock Jaffe Laboratories in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.28.
Buy
The current consensus among 1 polled investment analysts is to buy stock in Hancock Jaffe Laboratories.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/3/2020LADENBURG THALM/SH SHInitiated CoverageBuyHigh
i
1/9/2020Maxim GroupReiterated RatingBuy$3.00Low
i
11/20/2019Maxim GroupReiterated RatingBuy$3.00Medium
i
8/15/2019Maxim GroupReiterated RatingBuy$3.00Low
i
8/6/2019Maxim GroupInitiated CoverageBuy ➝ Buy$3.00High
i
(Data available from 2/26/2016 forward)
Hancock Jaffe Laboratories logo
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. operates as a subsidiary of Leman Cardiovascular SA.
Read More

Today's Range

Now: $7.28
$7.17
$7.52

50 Day Range

MA: $8.71
$7.49
$9.91

52 Week Range

Now: $7.28
$5.28
$20.25

Volume

10,152 shs

Average Volume

741,206 shs

Market Capitalization

$18.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Hancock Jaffe Laboratories?

The following sell-side analysts have issued stock ratings on Hancock Jaffe Laboratories in the last year: LADENBURG THALM/SH SH, and Zacks Investment Research.
View the latest analyst ratings for HJLI.

What is the current price target for Hancock Jaffe Laboratories?

0 Wall Street analysts have set twelve-month price targets for Hancock Jaffe Laboratories in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hancock Jaffe Laboratories in the next year.
View the latest price targets for HJLI.

What is the current consensus analyst rating for Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HJLI will outperform the market and that investors should add to their positions of Hancock Jaffe Laboratories.
View the latest ratings for HJLI.

What other companies compete with Hancock Jaffe Laboratories?

How do I contact Hancock Jaffe Laboratories' investor relations team?

Hancock Jaffe Laboratories' physical mailing address is 70 DOPPLER, IRVINE CA, 92618. The company's listed phone number is 949-261-2900. The official website for Hancock Jaffe Laboratories is www.hancockjaffe.com.